(0.32%) 5 116.41 points
(0.30%) 38 354 points
(0.37%) 15 988 points
(-0.98%) $83.03
(5.25%) $2.02
(0.29%) $2 353.90
(0.39%) $27.64
(4.13%) $960.15
(-0.27%) $0.932
(-0.45%) $10.98
(-0.57%) $0.796
(1.63%) $93.37
@ $21.84
発行日: 15 2月 2024 @ 05:27
リターン: 1.67%
前回のシグナル: 2月 10 - 03:56
前回のシグナル:
リターン: -3.36 %
Live Chart Being Loaded With Signals
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications...
Stats | |
---|---|
本日の出来高 | 103 357 |
平均出来高 | 237 943 |
時価総額 | 1.03B |
EPS | $0 ( 2024-03-13 ) |
次の収益日 | ( $-0.230 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -15.31 |
ATR14 | $0.0820 (0.37%) |
ボリューム 相関
Silence Therapeutics plc 相関
10 最も負の相関 | |
---|---|
RMRM | -0.876 |
SIBN | -0.859 |
SNPO | -0.847 |
APOP | -0.836 |
INZY | -0.828 |
RPHM | -0.821 |
HHGC | -0.815 |
HJLI | -0.812 |
GAINL | -0.808 |
VLCN | -0.804 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Silence Therapeutics plc 相関 - 通貨/商品
Silence Therapeutics plc 財務諸表
Annual | 2023 |
収益: | $25.38M |
総利益: | $15.06M (59.34 %) |
EPS: | $-1.170 |
FY | 2023 |
収益: | $25.38M |
総利益: | $15.06M (59.34 %) |
EPS: | $-1.170 |
FY | 2022 |
収益: | $17.50M |
総利益: | $6.62M (37.83 %) |
EPS: | $-1.260 |
FY | 2021 |
収益: | $12.42M |
総利益: | $4.96M (39.94 %) |
EPS: | $-1.329 |
Financial Reports:
No articles found.
Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。